Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
87373 trials found · Page 107 of 4369
-
New pill targets cancer's genetic weak spot in 15 tumor types
Disease control OngoingThis is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Apr 29, 2026 04:28 UTC
-
Womb transplants offer new hope for women born without a uterus
Disease control OngoingThis study aims to investigate the treatment of absolute uterine infertility (AUI) due to congenital or surgical absence of a uterus or presence of a nonfunctioning uterus. The investigators will follow a model based on a Swedish study to enroll 20 women with functioning ovaries …
Phase: NA • Sponsor: Baylor Research Institute • Aim: Disease control
Last updated Apr 13, 2026 20:22 UTC
-
New immunotherapy drug shows promise in preventing melanoma return after surgery
Disease control OngoingThis randomized phase III trial studies how well pembrolizumab works compared with the current standard of care, physician/patient choice of either high-dose recombinant interferon alfa-2B or ipilimumab, in treating patients with stage III-IV melanoma that has been removed by sur…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 26, 2026 19:39 UTC
-
Immunotherapy after lung cancer surgery shows promise in delaying return
Disease control CompletedIn this study, participants with Stage IB/II-IIIA non-small cell lung cancer (NSCLC) who have undergone surgical resection (lobectomy or pneumonectomy) with or without adjuvant chemotherapy will be treated with pembrolizumab or placebo. The primary study hypothesis is that pembro…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 24, 2026 16:07 UTC
-
Major trial pits new Immune-Boosting drugs against standard chemo for Tough-to-Treat cancer
Disease control OngoingA Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Stage IV Urothelial Cancer
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 15, 2026 16:15 UTC
-
Pill shows promise in stopping lung Cancer's comeback after surgery
Disease control OngoingTo assess the efficacy and safety of AZD9291 versus Placebo, in patients with Epidermal Growth Factor Receptor Mutation Positive stage IB-IIIA non-small cell lung carcinoma, following complete tumour resection with or without adjuvant chemotherapy
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 08, 2026 12:01 UTC
-
New targeted therapy outshines chemo in relapsed leukemia trial
Disease control CompletedThe purpose of this study was to determine the clinical benefit of ASP2215 therapy in participants with FMS-like tyrosine kinase (FLT3) mutated acute myeloid leukemia (AML) who were refractory to or had relapsed after first-line AML therapy as shown with overall survival (OS) com…
Phase: PHASE3 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Apr 26, 2026 19:36 UTC
-
New drug targets rare cancer gene, shows promise in advanced tumors
Disease control CompletedThis research study is done to test how well different types of cancer respond to the drug called larotrectinib. The cancer must have a change in a particular gene (NTRK1, NTRK2 or NTRK3). Larotrectinib is a drug that blocks the actions of these NTRK genes in cancer cells and can…
Phase: PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated Apr 08, 2026 12:03 UTC
-
Supercharged immune cells shrink tumors in advanced melanoma trial
Disease control CompletedProspective, interventional multicenter study evaluating adoptive cell therapy (ACT) via infusion of LN-144 (autologous TIL) followed by interleukin 2 (IL-2) after a nonmyeloablative lymphodepletion (NMA LD) preconditioning regimen.
Phase: PHASE2 • Sponsor: Iovance Biotherapeutics, Inc. • Aim: Disease control
Last updated Apr 28, 2026 13:02 UTC
-
Breakthrough 9-Month TB cure tested in gabon
⭐️ CURE ⭐️ CompletedThe principal objective is to evaluate a cure rate and number of adverse events of with confirmed multidrug-resistant tuberculosis patient treated with a 9months regimen.
Sponsor: Centre de Recherche Médicale de Lambaréné • Aim: ⭐️ CURE ⭐️
Last updated Apr 24, 2026 16:07 UTC
-
Brain implant lets Locked-In patients 'Talk' with their thoughts
Symptom relief CompletedIn this study a new means of communication for people with locked-in syndrome will be tested. The investigators will record brain signals directly from the surface of the brain by means of a completely implantable system. These brain signals are fed wirelessly into an assistive t…
Phase: NA • Sponsor: UMC Utrecht • Aim: Symptom relief
Last updated Mar 27, 2026 12:40 UTC
-
Which treatment first? landmark trial may guide melanoma care
Disease control OngoingThis phase III trial studies how well initial treatment with ipilimumab and nivolumab followed by dabrafenib and trametinib works and compares it to initial treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab in treating patients with stage III-IV melano…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 26, 2026 20:00 UTC
-
Immunotherapy showdown: new hope for advanced lung cancer patients
Disease control CompletedThe purpose of this study is to show that Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus Platinum-Doublet Chemotherapy improves progression free survival and/or overall survival compared with chemotherapy in patients with advanced lung cancer.
Phase: PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC
-
Leukemia treatment without chemo shows promise in new trial
Disease control OngoingThis phase III trial studies tretinoin and arsenic trioxide in treating patients with newly diagnosed acute promyelocytic leukemia. Standard treatment for acute promyelocytic leukemia involves high doses of a common class of chemotherapy drugs called anthracyclines, which are kno…
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Apr 24, 2026 16:19 UTC
-
Drug shows promise in stopping deadly skin Cancer's comeback
Disease control OngoingThis study will assess whether post-surgery therapy with pembrolizumab improves recurrence-free survival (RFS) as compared to placebo for high-risk participants with melanoma (Stage IIIA \[\> 1 mm metastasis\], IIIB and IIIC). The study will also assess whether pembrolizumab impr…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 14, 2026 13:10 UTC
-
Radiation boost could save rectums, spare patients from Life-Altering surgery
Disease control OngoingThe investigators propose to conduct a randomised study on cT2, cT3a-b tumours less than 5 cm using two different techniques of radiotherapy boost following neoadjuvant chemoradiotherapy (nCRT) (CAP45): EBRT (9 Gy/5 fractions) or CXB (90 Gy/3 fractions). The endpoint will be orga…
Phase: PHASE3 • Sponsor: Centre Antoine Lacassagne • Aim: Disease control
Last updated Apr 06, 2026 14:15 UTC
-
New hope for kids with aggressive brain cancers: early trial tests Immune-Boosting drug
Disease control OngoingThis phase I trial studies the side effects and best dose of pembrolizumab and to see how well it works in treating younger patients with high-grade gliomas (brain tumors that are generally expected to be fast growing and aggressive), diffuse intrinsic pontine gliomas (brain stem…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 13, 2026 20:17 UTC
-
Donor hand transplant trial aims to restore function after amputation
Disease control Recruiting nowThe purpose of this study is to see if an investigational surgery that transfers tissue from a non-living donor to living individual will help restore greater function, appearance, and sensation to the hand and forearm areas of individuals who have suffered traumatic injury to th…
Phase: NA • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Apr 07, 2026 14:36 UTC
-
Could starting HIV drugs at birth lead to a 'Functional Cure' for babies?
Disease control OngoingThe overall objective of this study is to determine whether very early antiretroviral treatment (ART) initiation in HIV-infected infants limits the seeding of viral reservoirs and maintains immune responses, potentially allowing future periods off ART.
Phase: PHASE2, PHASE3 • Sponsor: Harvard School of Public Health (HSPH) • Aim: Disease control
Last updated Mar 16, 2026 15:24 UTC
-
Brain cancer vaccine trial aims to boost survival
Disease control OngoingThis phase II trial studies the side effects and how well vaccine therapy works when given together with temozolomide in treating patients with newly diagnosed glioblastoma. Vaccines made from the survivin peptide or antigen may help the body build an effective immune response to…
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Mar 25, 2026 14:09 UTC